TAK 214

Drug Profile

TAK 214

Alternative Names: Norovirus bivalent vaccine - Takeda; Norovirus bivalent VLP vaccine; Norovirus GI.1/GII.4 bivalent VLP vaccine; Norovirus IM vaccine - Takeda; Norovirus intramuscular vaccine - Takeda; TAK-214

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LigoCyte Pharmaceuticals
  • Developer Takeda
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Norovirus infections

Most Recent Events

  • 04 Oct 2017 Immunogenicity and adverse events data from a phase II trial in Norovirus infections presented at the IDWeek 2017 (IDW-2017)
  • 21 Feb 2017 Takeda initiates enrolment in a phase II trial for Norovirus infections (Prevention) in USA (IM) (NCT03039790)
  • 02 Feb 2017 Takeda plans a follow-up phase II trial for Norovirus infections (Prevention) in USA and Belgium (IM) (NCT03039790)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top